This difference in sensitivity to the RAS–RAF–MEK–ERK pathway between ovarian cancer and the latter types is intriguing, and it probably reflects organ-specific roles of the KRAS and BRAF oncogenes. The gene discussed is KRAS; the disease is ovarian carcinoma.